抗体合作与许可协议：2019-2025

本报告全面深入分析了全球领先的生物製药公司签署的抗体相关协议，并提供前所未有的资讯管道。

本报告详细阐述并分析了公司签署抗体协议的原因和方法。这些协议通常包含多个组成部分，从合作研发开始，最终实现成果的商业化。

本报告涵盖合作研发、研究和授权协议。

本报告包​​含自2019年以来公布的1486项抗体交易的完整清单，其中包括可用的财务条款以及各方披露的实际抗体合作交易的线上记录连结。此外，在条件允许的情况下，记录中还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

主要优势：

• 了解2019年及以后的合约趋势
• 查看抗体领域的合作与授权协议
• 基准分析：确定交易市场价值
• 财务条款：预付款、里程碑付款、特许权使用费
• 依公司名称（A-Z）、合约类型和治疗领域分类的合约目录
• 以价值为排名的热门交易
• 最活跃的交易撮合者
• 识别每份合约的资产描述和条款
• 存取合约文件：深入了解合约结构
• 尽职调查：评估拟议合约条款是否适合您的合作伙伴
• 节省数百小时的研究时间

分析合约内容有助于进行以下方面的尽职调查：

• 合约授予或选择哪些具体权利？
• 合约实际授予合作伙伴哪些权利？
• 授予哪些独家销售权？
• 合约的付款结构是什么？
• 销售和付款将如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）将如何处理，所有权归谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更，会发生什么事？
• 双方约定的转授权和分包条款是什么？
• 公司通常会包含哪些标准条款？
• 哪些标准条款会因交易对手和合约类型而异？
• 根据合约法，该公司要求适用哪一方（法院）的管辖法律？

目录

摘要整理

第一章：引言

第二章：抗体合约趋势

• 过去几年抗体合约数量
• 最活跃的合约方
• 依合约类型划分的抗体合约
• 依治疗领域划分的抗体合约
• 依行业划分的抗体合约
• 抗体合约条款

第三章：主要抗体合约

• 以合约金额划分的主要抗体合约

第四章：最活跃的抗体合约方

• 最活跃的抗体合约方
• 最活跃的抗体合约方简介抗体承包商

第五章：抗体协议交易目录

• 抗体协议交易目录

第六章：以技术类型划分的抗体协议

• 协定目录
• 协议目录 - 依公司（A-Z）分类
• 协定目录 - 依协定类型分类
• 协议目录 - 依治疗领域分类
• 协定类型定义
• 关于 Biopharma Research Ltd
• 当前合作
• 当前协议
• 来自 Current Partnering 的最新报告标题

"抗体合作与许可协议报告" 全面深入分析了全球主要生物製药公司签署的抗体相关协议，并提供前所未有的存取权限。

这份经过全面修订和更新的报告详细介绍了2019年至2025年的抗体交易。

本报告深入分析了企业达成抗体协议的方式和原因。这些协议通常包含多个组成部分，从合作研发开始，逐步推进到成果的商业化。

本报告涵盖合作研发、研究和授权。

本报告包​​含自2019年以来公布的1486项抗体交易的完整列表，包括可用的财务条款以及指向交易双方披露的实际抗体合作交易在线记录的链接。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了抗体交易的趋势。

第一章概述了本报告。

第二章概述了自 2019 年以来的抗体交易趋势。

第三章概述了自 2019 年以来的主要抗体交易，并依交易总额排序。

第四章提供了最活跃的 25 家抗体交易撮合者的完整名单，并附有简要概述，随后提供了抗体交易和公开合约文件的完整清单。

第五章对自 2019 年 1 月以来已完成和宣布的、合约文件公开的抗体交易进行了全面深入的回顾。

第六章对自2019年1月以来已达成和公布的抗体合作协议进行了全面深入的回顾。本章依具体的抗体技术类型进行组织。

报告中还包含大量表格和图表，展示了自2019年以来抗体交易的趋势和活动。

此外，我们还提供了一个全面的合约目录，依公司名称（依字母顺序排列）、合约类型和治疗靶点进行分类。每个合约标题都连结到合约记录的线上版本，并在可用的情况下连结到合约文件，方便用户根据需要轻鬆存取每个合约文件。

主要优势

"抗体合作与许可协议报告" 提供读者以下主要优势：

• 了解 2019 年及以后的交易趋势
• 浏览抗体合作与许可协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 预付款、里程碑付款、特许权使用费
• 依公司（A-Z）、合约类型和治疗领域分类的合约目录
• 以交易价值排名的热门交易
• 最活跃的交易撮合者
• 识别每笔交易的资产描述和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间。

范围

• 本报告 "抗体合作与许可协议" 旨在帮助读者深入了解全球主要生物製药公司签订的抗体相关协议的趋势和结构。

本报告涵盖：

• 生物製药产业的抗体交易趋势
• 製药和生物技术公司抗体交易记录目录
• 以价值排名的主要抗体交易
• 最活跃的抗体许可协议
• "抗体合作与许可协议" 提供对现有交易记录的全面访问，包括合约文件（如有）。

分析合约内容可协助您对以下内容进行尽职调查：

• 协议授予或选择哪些具体权利？
• 合约实际上赋予合作伙伴哪些权利？
• 授予了哪些独家经营权？
• 交易的付款结构是怎么样的？
• 销售和付款如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）如何处理归属于谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更会发生什么事？
• 如何就分授权和分包条款达成协议？
• 贵公司要求哪些标准条款？
• 哪些标准条款会因合作伙伴和交易类型而异？
• 贵公司要求以哪个司法管辖区的法律作为合约的适用法律？

目录

摘要整理

第一章：引言

第二章：抗体交易趋势

• 引言
• 历年抗体交易
• 最活跃的抗体经销商
• 以交易类型划分的抗体交易
• 依治疗领域划分的抗体交易
• 依行业划分的抗体交易
• 抗体交易条款
  • 抗体交易的总额
  • 抗体交易中的预付款
  • 抗体交易中的里程碑付款
  • 抗体特许权使用费率

第三章：重要的抗体交易

• 引言
• 顶部以交易额划分的抗体交易

第四章 - 最活跃的抗体交易商

• 引言
• 最活跃的抗体交易商
• 最活跃的抗体交易商公司简介

第五章 - 抗体合约交易目录

• 引言
• 抗体合约交易目录

第六章 - 依技术类型划分的抗体交易

• 交易目录
• 依公司划分的抗体交易目录 (AZ)
• 以交易类型划分的抗体交易目录
• 依治疗领域划分的抗体交易目录
• 交易类型定义
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前协议
• 近期交易标题目前合作伙伴报告

Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibody deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1486 antibody deals announced since 2019 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

• Trends in antibody dealmaking in the biopharma industry
• Directory of antibody deal records covering pharmaceutical and biotechnology
• The leading antibody deals by value
• Most active antibody licensing dealmakers
• Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

• 2.1. Introduction
• 2.2. Antibody deals over the years
• 2.3. Most active antibody dealmakers
• 2.4. Antibody deals by deal type
• 2.5. Antibody deals by therapy area
• 2.6. Antibody deals by industry sector
• 2.7. Deal terms for antibody deals
  • 2.7.1 Antibody deals headline values
  • 2.7.2 Antibody deal upfront payments
  • 2.7.3 Antibody deal milestone payments
  • 2.7.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

• 3.1. Introduction
• 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

• 4.1. Introduction
• 4.2. Most active antibody dealmakers
• 4.3. Most active antibody deals company profiles

Chapter 5 - Antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

• Deal directory
• Deal directory - Antibody deals by company A-Z
• Deal directory - Antibody deals by deal type
• Deal directory - Antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Antibody deals since 2019
• Figure 2: Active antibody dealmaking activity - 2019 - 2025
• Figure 3: Antibody deals by deal type since 2019
• Figure 4: Antibody deals by therapy area since 2019
• Figure 5: Antibody deals by industry sector since 2019
• Figure 6: Antibody deals with a headline value
• Figure 7: Antibody deals with an upfront value
• Figure 8: Antibody deals with a milestone value
• Figure 9: Antibody deals with a royalty rate value
• Figure 10: Top antibody deals by value since 2019
• Figure 11: Most active antibody dealmakers 2019 - 2025
• Figure 12: Antibody deals by technology type since 2019